Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.

Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Chiron M, Yoshino T.

Cancer Sci. 2019 Sep 14. doi: 10.1111/cas.14198. [Epub ahead of print]

2.

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.

Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, Hironaka S, Kii T, Kojima Y, Akutsu Y, Matsushita H, Kawakami K, Mori K, Makiuchi T, Nagumo R, Kitagawa Y.

Ann Surg Oncol. 2019 Aug 2. doi: 10.1245/s10434-019-07654-8. [Epub ahead of print]

PMID:
31376034
3.

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer.

Honda K, Gyawali B, Ando M, Kumanishi R, Kato K, Sugiyama K, Mitani S, Masuishi T, Narita Y, Bando H, Taniguchi H, Kadowaki S, Ura T, Muro K.

J Glob Oncol. 2019 May;5:1-8. doi: 10.1200/JGO.19.00003.

4.

The binding affinity of uncharged aromatic solutes for negatively charged resins is enhanced by cations via cation-π interactions: The case of sodium ion and arginine.

Hirano A, Iwashita K, Ura T, Sakuraba S, Shiraki K, Arakawa T, Kameda T.

J Chromatogr A. 2019 Jun 21;1595:97-107. doi: 10.1016/j.chroma.2019.02.043. Epub 2019 Feb 21.

PMID:
30833023
5.

The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation.

Mitani S, Taniguchi H, Sugiyama K, Masuishi T, Honda K, Narita Y, Kadowaki S, Ura T, Ando M, Tajika M, Yatabe Y, Muro K.

Ther Adv Med Oncol. 2019 Jan 12;11:1758835918820298. doi: 10.1177/1758835918820298. eCollection 2019.

6.

Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.

Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Sunaga Y, Ziti-Ljajic S, Brillac C, Yoshino T.

Cancer Sci. 2019 Mar;110(3):1032-1043. doi: 10.1111/cas.13943. Epub 2019 Feb 22.

7.

Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases.

Masuishi T, Taniguchi H, Eto T, Komori A, Mitani S, Hasegawa H, Narita Y, Ishihara M, Tanaka T, Kadowaki S, Ura T, Ando M, Tajika M, Nomura M, Sato Y, Mishima H, Muro K.

Anticancer Res. 2018 Nov;38(11):6501-6506. doi: 10.21873/anticanres.13014.

PMID:
30396978
8.

Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.

Sugiyama K, Narita Y, Mitani S, Honda K, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Ando M, Tajika M, Muro K.

Anticancer Res. 2018 Oct;38(10):5859-5866. doi: 10.21873/anticanres.12928.

PMID:
30275211
9.

Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site.

Hasegawa H, Ando M, Yatabe Y, Mitani S, Honda K, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K.

Clin Oncol (R Coll Radiol). 2018 Oct;30(10):667-673. doi: 10.1016/j.clon.2018.06.012. Epub 2018 Jul 6.

PMID:
30196846
10.

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study.

Honda K, Gyawali B, Ando M, Sugiyama K, Mitani S, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K.

Ecancermedicalscience. 2018 Jul 5;12:847. doi: 10.3332/ecancer.2018.847. eCollection 2018.

11.

Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.

Kondoh C, Kadowaki S, Komori A, Narita Y, Taniguchi H, Ura T, Ando M, Muro K.

Gastric Cancer. 2018 Nov;21(6):1050-1057. doi: 10.1007/s10120-018-0825-y. Epub 2018 Apr 16.

PMID:
29658055
12.

Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale.

Masuishi T, Taniguchi H, Sugiyama K, Kato K, Mitani S, Honda K, Narita Y, Kadowaki S, Ura T, Ando M, Muro K.

Ann Oncol. 2018 May 1;29(5):1330-1331. doi: 10.1093/annonc/mdy107. No abstract available.

PMID:
29635451
13.

Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients.

Narita Y, Kadowaki S, Oze I, Kito Y, Kawakami T, Machida N, Taniguchi H, Ura T, Ando M, Ito S, Tajika M, Yatabe Y, Yasui H, Muro K.

J Gastrointest Oncol. 2018 Feb;9(1):52-63. doi: 10.21037/jgo.2017.11.08.

14.

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study.

Kato K, Ura T, Koizumi W, Iwasa S, Katada C, Azuma M, Ishikura S, Nakao Y, Onuma H, Muro K.

Cancer Sci. 2018 Mar;109(3):785-793. doi: 10.1111/cas.13481. Epub 2018 Feb 15.

15.

FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.

Masuishi T, Kadowaki S, Kondo M, Komori A, Sugiyama K, Mitani S, Honda K, Narita Y, Taniguchi H, Ura T, Ando M, Mishima H, Muro K.

Anticancer Res. 2017 Dec;37(12):7037-7042.

PMID:
29187492
16.

Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature.

Honda K, Ando M, Sugiyama K, Mitani S, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K.

Case Rep Oncol. 2017 Sep 21;10(3):863-870. doi: 10.1159/000481194. eCollection 2017 Sep-Dec.

17.

Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin.

Maeda A, Ando H, Ura T, Muro K, Aoki M, Saito K, Kondo E, Takahashi S, Ito Y, Mizuno Y, Fujimura A.

Anticancer Res. 2017 Sep;37(9):5235-5239.

PMID:
28870959
18.

Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.

Komori A, Taniguchi H, Hamauchi S, Masuishi T, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K.

Oncology. 2017;93(5):329-335. doi: 10.1159/000479280. Epub 2017 Sep 2.

PMID:
28866662
19.

Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.

Kadowaki S, Masuishi T, Eto T, Narita Y, Taniguchi H, Ura T, Ando M, Tajika M, Niwa Y, Yatabe Y, Muro K.

Cancer Chemother Pharmacol. 2017 Oct;80(4):807-813. doi: 10.1007/s00280-017-3422-6. Epub 2017 Aug 18.

PMID:
28821938
20.

Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer.

Narita Y, Kadowaki S, Masuishi T, Taniguchi H, Takahari D, Ura T, Ando M, Tajika M, Niwa Y, Eto T, Hara H, Asayama M, Yamaguchi K, Yatabe Y, Muro K.

Oncol Lett. 2017 Aug;14(2):2545-2551. doi: 10.3892/ol.2017.6409. Epub 2017 Jun 19.

21.

Chemoradiation therapy with docetaxel in elderly patients with stage II/III esophageal cancer: A phase 2 trial.

Ohba A, Kato K, Ito Y, Katada C, Ishiyama H, Yamamoto S, Ura T, Kodaira T, Kudo S, Tamaki Y.

Adv Radiat Oncol. 2016 Jul 15;1(4):230-236. doi: 10.1016/j.adro.2016.07.002. eCollection 2016 Oct-Dec.

22.

Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature.

Mitani S, Kadowaki S, Komori A, Sugiyama K, Narita Y, Taniguchi H, Ura T, Ando M, Sato Y, Yamaura H, Inaba Y, Ishihara M, Tanaka T, Tajika M, Muro K.

Medicine (Baltimore). 2017 Jun;96(22):e6874. doi: 10.1097/MD.0000000000006874. Review.

23.

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.

Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S, Hara H, Satoh T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Kitagawa Y.

Lancet Oncol. 2017 May;18(5):631-639. doi: 10.1016/S1470-2045(17)30181-X. Epub 2017 Mar 15.

PMID:
28314688
24.

Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study
.

Maeda A, Ando H, Ura T, Komori A, Hasegawa A, Taniguchi H, Kadowaki S, Muro K, Tajika M, Kobara M, Matsuzaki M, Hashimoto N, Maeda M, Kojima Y, Aoki M, Kondo E, Mizutani A, Fujimura A.

Int J Clin Pharmacol Ther. 2017 May;55(5):409-415. doi: 10.5414/CP202788.

PMID:
28157071
25.

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.

Hasegawa H, Taniguchi H, Mitani S, Masuishi T, Komori A, Narita Y, Kadowaki S, Ura T, Ando M, Yatabe Y, Muro K.

Oncology. 2017;92(4):205-212. doi: 10.1159/000453336. Epub 2017 Feb 1.

PMID:
28142137
26.

Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure.

Sato Y, Inaba Y, Ura T, Nishiofuku H, Yamaura H, Kato M, Takahari D, Tanaka T, Muro K.

J Gastrointest Cancer. 2018 Jun;49(2):132-137. doi: 10.1007/s12029-016-9915-4.

PMID:
28058527
27.

Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation.

Sugiyama K, Narita Y, Kadowaki S, Ura T, Tajika M, Muro K.

Anticancer Res. 2017 Jan;37(1):309-313.

PMID:
28011507
28.

Cytosolic Transport of Nanoparticles through Pressurized Plasma Membranes for Molecular Delivery and Amplification of Intracellular Fluorescence.

Kaizuka Y, Ura T, Lyu S, Chao L, Henzie J, Nakao H.

Langmuir. 2016 Dec 20;32(50):13534-13545. Epub 2016 Dec 6.

PMID:
27993015
29.

Intradermal Delivery of Antigens Enhances Specific IgG and Diminishes IgE Production: Potential Use for Vaccination and Allergy Immunotherapy.

Yasuda T, Ura T, Taniguchi M, Yoshida H.

PLoS One. 2016 Dec 14;11(12):e0167952. doi: 10.1371/journal.pone.0167952. eCollection 2016.

30.

Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.

Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, Hironaka S, Kii T, Kojima Y, Akutsu Y, Matsushita H, Kawakami K, Mori K, Nagai Y, Asami C, Kitagawa Y.

Br J Cancer. 2016 Nov 22;115(11):1328-1334. doi: 10.1038/bjc.2016.350. Epub 2016 Nov 3.

31.

Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.

Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K.

Clin Colorectal Cancer. 2017 Jun;16(2):e15-e22. doi: 10.1016/j.clcc.2016.07.019. Epub 2016 Aug 31.

PMID:
27670892
32.

Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors.

Takahashi S, Nakano K, Yokota T, Shitara K, Muro K, Sunaga Y, Ecstein-Fraisse E, Ura T.

Jpn J Clin Oncol. 2016 Aug 27. [Epub ahead of print]

PMID:
27566973
33.

Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.

Hamauchi S, Yamazaki K, Masuishi T, Kito Y, Komori A, Tsushima T, Narita Y, Todaka A, Ishihara M, Yokota T, Tanaka T, Machida N, Kadowaki S, Fukutomi A, Ura T, Onozawa Y, Ando M, Tajika M, Muro K, Yasui H, Mori K, Taniguchi H.

Clin Colorectal Cancer. 2017 Mar;16(1):51-57. doi: 10.1016/j.clcc.2016.07.005. Epub 2016 Jul 21.

PMID:
27522626
34.

A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.

Maeda A, Ura T, Asano C, Haegawa I, Nomura M, Komori A, Narita Y, Taniguchi H, Kadowaki S, Muro K, Horio Y, Yoshida T, Oze I, Kajita M, Mizutani A.

Asia Pac J Clin Oncol. 2016 Sep;12(3):254-8. doi: 10.1111/ajco.12489. Epub 2016 Mar 31.

PMID:
27030364
35.

Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.

Nomura M, Oze I, Kodaira T, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Tachibana H, Uemura N, Tajika M, Niwa Y, Muto M, Muro K.

Int J Clin Oncol. 2016 Oct;21(5):890-898. Epub 2016 Mar 15.

PMID:
26980212
36.

A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.

Taniguchi H, Komori A, Narita Y, Kadowaki S, Ura T, Andoh M, Yatabe Y, Komori K, Kimura K, Kinoshita T, Muro K.

Jpn J Clin Oncol. 2016 Mar;46(3):228-33. doi: 10.1093/jjco/hyv193. Epub 2016 Jan 12.

PMID:
26759349
37.

Self-assessment of Rheumatoid Arthritis Disease Activity Using a Smartphone Application. Development and 3-month Feasibility Study.

Nishiguchi S, Ito H, Yamada M, Yoshitomi H, Furu M, Ito T, Shinohara A, Ura T, Okamoto K, Aoyama T, Tsuboyama T.

Methods Inf Med. 2016;55(1):65-9. doi: 10.3414/ME14-01-0106. Epub 2015 Sep 22.

PMID:
26391694
38.

A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.

Yamaguchi K, Taniguchi H, Komori A, Narita Y, Nitta S, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K, Mori K, Igarashi Y.

BMC Cancer. 2015 Aug 27;15:601. doi: 10.1186/s12885-015-1606-1.

39.

Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study.

Kondoh C, Shitara K, Nomura M, Takahari D, Ura T, Tachibana H, Tomita N, Kodaira T, Muro K.

BMC Palliat Care. 2015 Aug 4;14:37. doi: 10.1186/s12904-015-0034-y.

40.

Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy.

Kadowaki S, Komori A, Takahari D, Ura T, Ito S, Tajika M, Niwa Y, Oze I, Muro K.

Asian Pac J Cancer Prev. 2015;16(13):5433-8.

41.

Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.

Nomura M, Oze I, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Kawai R, Uemura N, Ishihara M, Tanaka T, Tajika M, Niwa Y, Muro K, Muto M.

Cancer Chemother Pharmacol. 2015 Aug;76(2):357-63. doi: 10.1007/s00280-015-2806-8. Epub 2015 Jun 20.

PMID:
26092324
42.

[A questionnaire survey on QOL and toxicity in colorectal cancer survivors who received adjuvant chemotherapy].

Taniguchi H, Narita Y, Komori K, Kimura K, Kinoshita T, Komori A, Uegaki S, Nomura M, Nitta S, Yamaguchi K, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K.

Gan To Kagaku Ryoho. 2015 Apr;42(4):457-61. Japanese.

PMID:
25963692
43.

Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).

Suenaga M, Nishina T, Mizunuma N, Yasui H, Ura T, Denda T, Ikeda J, Esaki T, Nishisaki H, Takano Y, Sugiyama Y, Muro K.

BMC Cancer. 2015 Mar 25;15:176. doi: 10.1186/s12885-015-1175-3.

44.

Differences in attitude toward adjuvant chemotherapy between colorectal cancer survivors and the medical staff of Japanese hospitals.

Narita Y, Taniguchi H, Komori K, Kimura K, Kinoshita T, Komori A, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K.

Int J Clin Oncol. 2015 Aug;20(4):755-60. doi: 10.1007/s10147-014-0772-5. Epub 2014 Nov 27.

PMID:
25424249
45.

A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).

Hamamoto Y, Yamaguchi T, Nishina T, Yamazaki K, Ura T, Nakajima T, Goto A, Shimada K, Nakayama N, Sakamoto J, Morita S, Yamada Y.

Oncologist. 2014 Nov;19(11):1131-2. doi: 10.1634/theoncologist.2014-0159. Epub 2014 Oct 3.

46.

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations.

Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, Hamada Y, Ohtsu A.

Invest New Drugs. 2015 Jun;33(3):740-50. doi: 10.1007/s10637-014-0154-x. Epub 2014 Sep 12.

47.

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.

Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, Yamada Y, Ura T, Kim SY, Munakata M, Saitoh S, Nishio K, Morita S, Yamamoto E, Zhang Q, Kim JM, Kim YH, Sakata Y.

Gastric Cancer. 2015 Oct;18(4):824-32. doi: 10.1007/s10120-014-0420-9. Epub 2014 Sep 5.

48.

Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).

Hironaka S, Tsubosa Y, Mizusawa J, Kii T, Kato K, Tsushima T, Chin K, Tomori A, Okuno T, Taniki T, Ura T, Matsushita H, Kojima T, Doki Y, Kusaba H, Fujitani K, Taira K, Seki S, Nakamura T, Kitagawa Y; Japan Esophageal Oncology Group/Japan Clinical Oncology Group.

Cancer Sci. 2014 Sep;105(9):1189-95. doi: 10.1111/cas.12486.

49.

Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.

Sasaki Y, Hamaguchi T, Arai T, Goto A, Ura T, Muro K, Yamada Y, Shirao K, Shimada Y.

Anticancer Res. 2014 Apr;34(4):2029-34.

PMID:
24692743
50.

Self-assessment tool of disease activity of rheumatoid arthritis by using a smartphone application.

Nishiguchi S, Ito H, Yamada M, Yoshitomi H, Furu M, Ito T, Shinohara A, Ura T, Okamoto K, Aoyama T.

Telemed J E Health. 2014 Mar;20(3):235-40. doi: 10.1089/tmj.2013.0162. Epub 2014 Jan 3.

Supplemental Content

Support Center